These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 5952216)

  • 1. The problem of adverse drug reactions.
    Wintrobe MM
    JAMA; 1966 May; 196(5):404-5. PubMed ID: 5952216
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse drug reactions.
    Barclay WR
    JAMA; 1979 Aug; 242(7):656. PubMed ID: 449007
    [No Abstract]   [Full Text] [Related]  

  • 3. The present status of adverse drug reaction reporting.
    Weston JK
    JAMA; 1968 Jan; 203(1):35-7. PubMed ID: 5694081
    [No Abstract]   [Full Text] [Related]  

  • 4. AMA-DE II.
    Ballin JC
    JAMA; 1973 Jul; 225(5):517. PubMed ID: 4740342
    [No Abstract]   [Full Text] [Related]  

  • 5. Experience in monitoring drug reactions in outpatients. The Kaiser-Permanente Drug Monitoring System.
    Friedman GD; Collen MF; Harris LE; Van Brunt EE; Davis LS
    JAMA; 1971 Aug; 217(5):567-72. PubMed ID: 5109088
    [No Abstract]   [Full Text] [Related]  

  • 6. Reporting adverse drug reactions.
    JAMA; 1966 May; 196(5):429-30. PubMed ID: 5952225
    [No Abstract]   [Full Text] [Related]  

  • 7. The American Medical Association Registry on Adverse Reactions.
    De Nosaquo N
    Ann Intern Med; 1966 Jun; 64(6):1325-7. PubMed ID: 5952387
    [No Abstract]   [Full Text] [Related]  

  • 8. Discovery of new adverse drug reactions. A review of the Food and Drug Administration's spontaneous reporting system.
    Rossi AC; Knapp DE
    JAMA; 1984 Aug 24-31; 252(8):1030-3. PubMed ID: 6748207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovering adverse drug reactions.
    Lasagna L
    JAMA; 1983 Apr 22-29; 249(16):2224-5. PubMed ID: 6339764
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse drug reactions: definition of the problem.
    Dunlop D
    Am J Epidemiol; 1971 Nov; 94(5):403-4. PubMed ID: 5120537
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse drug reactions--a continuing problem.
    Feldmann EG
    J Pharm Sci; 1983 Jun; 72(6):585. PubMed ID: 6875814
    [No Abstract]   [Full Text] [Related]  

  • 12. Council on drugs. To label or not to label.
    JAMA; 1965 Dec; 194(12):1311. PubMed ID: 5898088
    [No Abstract]   [Full Text] [Related]  

  • 13. AMA registry on adverse drug reactions.
    De Nosaquo N
    J Am Pharm Assoc; 1966 Feb; 6(2):66-8. PubMed ID: 5951869
    [No Abstract]   [Full Text] [Related]  

  • 14. The promise of pharmacoepidemiology.
    Strom BL
    Annu Rev Pharmacol Toxicol; 1987; 27():71-86. PubMed ID: 3555321
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety concerns at the FDA.
    Lancet; 2005 Feb 26-Mar 4; 365(9461):727-8. PubMed ID: 15733696
    [No Abstract]   [Full Text] [Related]  

  • 16. The obituary of an idea.
    Moser RH
    JAMA; 1971 Jun; 216(13):2135-6. PubMed ID: 5108678
    [No Abstract]   [Full Text] [Related]  

  • 17. The Food and Drug Administration's role in promoting consistent labels for generic drugs.
    Duke JD; Kesselheim AS
    JAMA Intern Med; 2014 Aug; 174(8):1213-4. PubMed ID: 24957047
    [No Abstract]   [Full Text] [Related]  

  • 18. Improving detection of adverse effects of marketed drugs.
    Klein DF; O'Brien CP
    JAMA; 2007 Jul; 298(3):333-4. PubMed ID: 17635895
    [No Abstract]   [Full Text] [Related]  

  • 19. Reporting drug side effects: signals and noise.
    Avorn J
    JAMA; 1990 Apr; 263(13):1823. PubMed ID: 2313853
    [No Abstract]   [Full Text] [Related]  

  • 20. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
    Qato DM; Alexander GC
    JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.